Long-term safety and efficacy of selective laser trabeculoplasty as primary therapy for the treatment of pseudoexfoliation glaucoma compared with primary open-angle glaucoma by Shazly, Tarek A et al.
© 2011 Shazly et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2011:5 5–10
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
5
OriginAL reSeArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S15952
Long-term safety and efficacy of selective  
laser trabeculoplasty as primary therapy  
for the treatment of pseudoexfoliation glaucoma 
compared with primary open-angle glaucoma
Tarek A Shazly1,2
Jan Smith3
Mark A Latina4
1Ophthalmology Department, 
Massachusetts eye and ear infirmary, 
harvard Medical School, Boston,  
MA, USA; 2Ophthalmology, Assiut 
University hospital, Assiut, egypt; 
3Oslo eye institute, Oslo, norway; 
4reading health Center, reading,  
MA, USA
Correspondence: Tarek A Shazly
20 Pondmeadow Dr Ste 203,  
reading, MA, US 01867
Tel +1 781 942 9876
Fax +1 781 942 9877
email shazlyt@gmail.com
Purpose: To investigate the safety and efficacy of selective laser trabeculoplasty (SLT) to 
reduce intraocular pressure (IOP) in patients with pseudoexfoliation glaucoma (PXFG) compared 
with primary open-angle glaucoma (POAG).
Design: Non-randomized, prospective, clinical trial.
Methods: Nineteen eyes of 13 patients with POAG and 18 eyes of 13 patients with PXFG 
were treated with SLT. Patients were followed without antiglaucoma medications until additional 
medical, laser, or surgical intervention was initiated, at which time they were considered failures, 
had withdrawn from the study, or underwent a second SLT.
Results: The POAG and PXFG eyes showed similar reductions of IOP over the 49 months of 
follow-up. At 30 months of follow-up the POAG group showed a mean IOP of 17.6 ± 2.8 mmHg 
and a mean IOP reduction of 5.7 ± 2.1 mmHg; the PXFG group showed a mean IOP of 18.3 ± 4.7 
and a mean IOP reduction of 5.3 ± 3.0 mmHg. Four eyes in the PXFG group and three eyes in 
the POAG group failed by 30 months. The cumulative probability of success was 74% for the 
PXFG group and 77% for the POAG group. Four PXFG eyes underwent a second SLT after 
30 months of follow-up with a final IOP of 17.6 ± 2.8 mmHg. There were no serious adverse 
events.
Conclusion: SLT is a safe and effective method to lower IOP in patients with PXFG as initial 
glaucoma therapy. Both groups showed similar IOP reductions and failure rates.
Keywords: glaucoma, selective laser trabeculoplasty, primary open angle glaucoma, 
  pseudoexfoliation glaucoma, intraocular pressure, laser, trabecular meshwork
Introduction
The early work of Worthen and Wickham1,2 established that a continuous-wave argon 
laser could be used safely to photocoagulate the trabecular meshwork, with significant 
decreases in intraocular pressure (IOP) that were maintained over a period of months. 
Several years later, Wise and Witter used lower laser energy in the procedure known 
as argon laser trabeculoplasty (ALT). They reported a successful reduction of IOP in 
a population of patients who had failed medical therapy.3
The Glaucoma Laser Trial (GLT)3–6 demonstrated that initial treatment with ALT 
was shown to have a greater pressure-lowering effect than medication (timolol maleate 
0.5%) at 2 years of follow-up. The GLT study indicated that initial treatment with 
ALT in patients with primary open-angle glaucoma (POAG) was at least as effective 
as intervention with timolol.6Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Latina and Park7 demonstrated that a 532 nm Q-switched 
Nd:YAG laser with nanosecond pulse duration is capable of 
selectively targeting pigmented trabecular meshwork cells 
without collateral thermal damage to the adjacent nonpig-
mented trabecular meshwork cells and underlying trabecular 
beams.
A pilot study evaluating the IOP-lowering effect of selec-
tive laser trabeculoplasty (SLT) in 53 patients whose IOP 
could not be controlled by medications or who had failed 
traditional ALT8 demonstrated the safety and efficacy of SLT. 
The patients were followed up for 26 weeks, and a mean IOP 
reduction of 18.7% (4.6 mmHg) was seen with minimal 
adverse effects. Furthermore, 66% of patients who had previ-
ously failed ALT showed an average of 5.9 mmHg IOP 
reduction without any significant adverse effects.
The authors embarked on a prospective study to establish 
the safety and effectiveness of SLT as initial therapy to reduce 
IOP in patients with POAG and pseudoexfoliation glaucoma 
(PXFG).
Materials and methods
Patients with POAG or PXFG were considered eligible for 
this study if they met the following entry criteria: 1) were 18 
years of age or older; 2) had two sighted eyes; 3) had one of 
the following in the eye to be treated (a) uncontrolled POAG 
or (b) PXFG; 4) had no prior medical, laser, or surgical 
therapy for treatment of POAG; 5) would be considered a 
candidate for laser trabeculoplasty; and 6) were willing to 
provide written informed consent.
Patients with the following findings were excluded 
from the study: 1) those with any of the following in the 
eye to be treated (a) evidence of glaucoma other than 
POAG (eg, angle closure, inflammatory, or neovascular), 
(b) any ocular condition precluding adequate visualization 
and treatment of the trabecular meshwork, (c) prior treat-
ment with medical therapy, glaucoma surgery, or laser 
trabeculoplasty other than peripheral iridotomy; 2) any 
evidence of mental impairment that precluded the patient 
from understanding the protocol or the inability to sign 
an informed consent; 3) pregnancy; 4) potential need for 
other ocular surgery within 6 months of initial treatment; 
and 5) potential need for treatment with systemic steroids 
or having a concurrent condition warranting treatment 
with systemic steroids.
Patients were recruited by Mark A Latina (Reading Health 
Center, Reading, MA, USA) and Jan Smith (Oslo Eye 
  Institute, Oslo, Norway). The study was approved by the 
  Institutional Review Boards at the participating institutions.
A full ophthalmologic examination of both eyes was 
conducted 2–6 weeks prior to treatment (first screening 
examination), which included best corrected visual acuity, 
two readings of IOP determinations by Goldmann applana-
tion tonometry, slit lamp examination of the anterior segment 
(conjunctival injection; cornea, iris, and lens appearance; 
presence of anterior chamber cells and flare), gonioscopy 
(grading of pigmentation, presence of peripheral anterior 
synechiae, and evaluation of angle opening), fundus exami-
nation (including evaluation of cup:disc ratio and pallor), 
visual field examination, and the recording of glaucoma 
medications (type, dosage, and date, and time of last medica-
tion administration). Patient demographic information (sex 
and date of birth) and medical history, including previous 
ocular surgery, were also recorded.
Each investigator used his or her clinical judgment to 
determine which eye would be treated based on current IOP 
and general ocular and visual status of the eye.
The procedure was performed with topical proparacaine 
for anesthesia. Laser treatment was performed with a   Coherent 
Selecta 7000 Frequency Doubled Nd:YAG ophthalmic laser 
(Coherent, Inc, Palo Alto, CA, USA). The laser is a frequency- 
doubled Q-switched Nd:YAG laser that delivers 532 nm 
wavelength of laser light at a pulse duration of 3 nanoseconds 
and a spot size of 400 microns. The pulse energy ranges from 
0.1 to 1.2 mJ/pulse.
A Goldman three-mirror goniolens was placed on the eye 
with methylcellulose 1%. The nasal 180 degrees was treated 
in all eyes. To determine the optimum energy level for SLT 
for each eye, the laser energy was initially set at 0.8 mJ, and 
then the energy level was increased by 0.1 mJ until a micro-
cavitation bubble formation was observed. Treatment was 
then continued in a single pulse mode at the treatment energy 
level until 50 ± 10 contiguous but nonoverlapping 400 µm 
laser spots were created along 180 degrees of the nasal side 
of the trabecular meshwork. Bubble formation was monitored 
with each pulse. The total number of pulses delivered and 
the total amount of laser energy delivered were recorded.
Immediately after laser treatment, at the discretion of the 
treating physician, prednisolone acetate (1%) drops were 
administered and continued in the treated eye three to four 
times daily for 3 to 4 days. The IOP in the treated eye was 
assessed and recorded 1 hour postoperatively. If there was an 
IOP rise greater than 5 mmHg from the immediate preopera-
tive IOP, the elevation of the IOP was treated with appropriate 
antiglaucoma medications and recorded. The presence and 
level of cells in the anterior chamber were recorded. Any 
immediate postoperative complications were recorded.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Patients were evaluated at 3 weeks, 3 months, 6 months, 
9 months, and 15 months, with additional follow-up at 
3-month intervals for up to 42 months. At each postoperative 
visit, the best corrected visual acuity and IOP were measured, 
and slit lamp examination was performed (noting for con-
junctival injection; anterior chamber cell and flare; cornea, 
lens, and iris appearance). All major and minor complications 
and complaints were recorded and treated appropriately.
All ocular medications were recorded before surgery 
and at each subsequent visit. Medication changes or adjust-
ments made at the physician’s discretion were recorded. 
Patients that were started on antiglaucoma medications 
following SLT were considered failures and removed from 
the study.
Success/failure criteria
The primary outcome of this clinical trial was to evaluate the 
IOP response to SLT in patients without requiring any antiglau-
coma medications or additional laser or surgical therapy. Eyes 
were considered successes as long as the IOP did not return to 
baseline (,3 mmHg) and/or no further medical, laser, or surgi-
cal intervention for the treatment of glaucoma was initiated. 
Eyes were included in the analysis of each time interval until 
an intervention occurred, at which point they were considered 
failures and removed from subsequent follow-up periods. 
Patients were excluded from analysis at any subsequent fol-
low-up interval if they underwent cataract surgery or failed to 
reach the specified follow-up exam interval.
Analysis
A Student’s t-test for paired data was used to assess the 
changes in IOP from baseline values and differences between 
the groups.
Results
A total of 37 eyes in 26 patients were treated with SLT. 
Nineteen eyes in 13 patients had the diagnosis of POAG, and 
18 eyes in 13 patients had the diagnosis of PXFG. The POAG 
group consisted of seven males (53.8%) and six females 
(46.2%) with an average age of 71 years. The PXFG group 
consisted of nine females (69.2%) and four males (30.8%) 
with an average age of 74 years. Patients in the POAG group 
were followed for an average of 27.1 months and 20.4 months 
in the PXFG group. The demographic attributes, baseline 
characteristics, and treatment parameters are shown in 
Table 1.
After the 3-month follow-up visit, patients returned at 
various time intervals with up to 49 months of follow-up. 
For this reason, analysis of IOPs was performed on the last 
IOP taken with the time intervals 9–15 months post-  treatment, 
21–27 months post-treatment, and 30 months or more 
  post-treatment, which allowed at least one IOP measurement 
for each patient within the specified time interval.
As shown in Table 2, Table 3, and Figure 1, the POAG 
and PXFG groups showed statistically significant mean IOP 
Table 1 Demographics and baseline characteristics
Demographic Value
number of subjects 26
Treatment group
POAg 13 (50%)
PXFg 13 (50%)
Number of eyes
POAg 19
PXFg 15
Age
POAg mean 71
POAg range 59–81
PXFg mean 74
PXFg range 67–87
Sex
POAg male 7 (55.8%)
POAg female 6 (46.2%)
PXFg male 4 (30.8%)
PXFg female 9 (69.2%)
Race
Caucasian 100%
Abbreviations: POAg, primary open-angle glaucoma; PXFg, pseudoexfoliation 
glaucoma.
Table 2 iOP reduction from SLT when used as primary therapy 
for patients with POAg (n = 19 eyes from 13 patients)
Descriptive data
Time interval Number  
available
IOP (in mmHg)
Mean (SD) Range
Pre-SLT 19 23.2 (3.0) 17–28
3 months 19 17.2 (2.7) 11–22
9–15 months 19 18.1 (3.3) 13–23
21–27 months 14 18.9 (3.9) 15–30
30–42 months 11 17.6 (2.8) 13–21
Notes: Mean follow-up 27.1 months (range 6–42 months).
Comparative data
Time interval Number 
available
IOP reduction  
(in mmHg)
Mean (SD) P-valuea
Pre-SLT to 9–15 months 19 5.1 (2.4) ,0.0001
Pre-SLT to 21–27 months 14 4.9 (2.9) ,0.0001
Pre-SLT to 30+ months 11 5.7 (2.1) ,0.0001
Notes: aPaired Student’s t-test of the null hypothesis that the mean reduction in 
iOP equals zero.
Abbreviations: iOP, intraocular pressure; POAg, primary open-angle glaucoma; 
SD, standard deviation; SLT, selective laser trabeculoplasty.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
8
Shazly et al
reductions from baseline at each time interval. At 
30–42 months of follow-up, the mean IOP for the POAG 
group (17.6 ± 2.8 mmHg) was slightly lower than the PXFG 
group (18.3 + 4.7 mmHg) (30–32 months follow-up), 
although this was not significant.
As noted in Table 3, four eyes underwent a second SLT 
procedure in the PXFG group after the 30- to 32-month 
  follow-up period. All of these eyes remained off medications 
by the 30- to 32-month follow-up period and were considered 
successes at that time period. One eye received a second SLT 
at 32 months and was followed for an additional 12 months.
Two of the eyes received SLT at 32 months with an 
additional 3 months of follow-up, and one eye at 42 months 
with follow-up for up to 49 months. The mean IOP at the 
last follow-up visit for all 10 PXFG eyes without antiglau-
coma medications and having undergone either one or two 
SLT treatments was 17.9 + 2.1 mmHg with a mean IOP 
reduction of 5.5 + 3.3 mmHg.
Tables 4 and 5 demonstrate the number of eyes followed 
at each time interval, the number of eyes that were determined 
to be failures, and the number of eyes withdrawn due to loss 
to follow-up or another intervention such as cataract surgery, 
which removed them from further follow-up (Figure 2). 
The number of eyes reported in Tables 1 and 2 at each time 
interval represent those eyes that reached the follow-up interval 
without having been withdrawn at an earlier time period due 
to failure or another intervention such as cataract surgery.
By 30 months of follow-up, four eyes (22%) in the PXFG 
group and three eyes (16%) in the POAG group required 
initiation of medical or additional laser therapy and were 
classified as failures. As shown in Tables 4 and 5, following 
initial therapy with SLT, the probability of successfully 
remaining off medications without a second SLT at 
30 months is 77% for the POAG group and 74% for the 
PXFG group. It should be noted that 3/4 eyes failed within 
the first 9–15 months in the PXFG group with a cumulative 
probability of success of 0.83 compared with the POAG eyes, 
which tended to fail by the 30-month follow-up period.
In the PXFG group, one eye required further surgical 
intervention at 6 months, although the IOP reduction follow-
ing SLT was greater than 3 mmHg. Two eyes were started 
on antiglaucoma medications at the 9–15 months post-
treatment interval because the IOP returned to baseline. At the 
21-month follow-up period, one eye underwent ALT and 
was considered a failure.
A total of six eyes in the PXFG group were withdrawn up 
to the 30- to 32-month follow-up period for the following: one 
eye underwent cataract surgery before the 9th month follow-up 
period and was removed from the study; two eyes were not 
followed for longer than 16 months and one eye underwent 
cataract surgery at 17 months (these were considered successes, 
although they were not included in the follow-up periods 
beyond the 9–15 month period); and two eyes did not have 
IOPs measured at the 30-month follow- up period but remained 
off medications until 42 months, at which time one of the eyes 
underwent an additional SLT treatment and the other eye was 
followed for 45 months. For this reason, eight eyes are reported 
at 30–32 months without medications. However, 10 eyes are 
reported beyond the 30- to 32-month follow-up period.
In the POAG group, failures were accounted for as 
  follows: medical therapy was initiated in one eye at 9 months 
and in one eye following the 21-month follow-up period and 
one eye underwent ALT at 30 months and was removed from 
the study. A total of five eyes were withdrawn from follow-up 
over the course of the study for the following: one patient 
was followed for 12 months; two eyes were followed for 
17 months; one patient had an iridotomy at 18 months and 
was removed from further follow-up; and one eye underwent 
cataract surgery at 22 months and was removed from the 
study. The remaining 11 patients were followed for at least 
30 months without antiglaucoma medications.
There were no significant adverse events in any patients 
studied other than 1 hour postoperative pressure spikes, which 
Table 3 iOP reduction from SLT when used as primary therapy 
for patients with PXFg glaucoma (n = 18 eyes from 13 patients)
Descriptive data
Time interval Number  
available
IOP (in mmHg)
Mean (SD) Range
Pre-SLT 18 25.5 (3.4) 20–32
3 months 18 18.8 (3.0) 14–24
9–15 months 16 20.4 (4.2) 14–31
21–27 months 10 18.6 (1.9) 15–21
30–32 monthsa 8 18.3 (4.7) 12–25
33–49 monthsb 10 17.9 (2.1) 14–20
Notes: ano additional SLT – mean follow-up 20.4 months (range 3–42 months); 
bSecond SLT after 32 months in four patients – mean follow-up 41.2 months (range 
33–49 months).
Comparative data
Time interval Number  
available
IOP reduction (in mmHg)
Mean (SD) P-valuea
Pre-SLT to 9–15 months 16 4.9 (3.0) ,0.0001
Pre-SLT to 21–27 months 10 4.8 (3.0) 0.001
Pre-SLT to 30–32 monthsa 8 5.3 (3.0) 0.019
Pre-SLT to 33–49 monthsb 10 5.5 (3.3) 0.0005
Notes: Paired Student’s t-test of the null hypothesis that the mean reduction in iOP 
equals zero. ano additional SLT; bSecond SLT in four patients.
Abbreviations:  iOP,  intraocular  pressure;  PXFg,  pseudoexfoliation  glaucoma;   
SD, standard deviation; SLT, selective laser trabeculoplasty.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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responded to medical treatment with Iopidine® (Alcon, Forth 
Worth, TX, USA). In the PXFG group, 5 of 18 patients (28%) 
showed an IOP spike of greater than 5 mmHg, although only 
one patient (5.5%) showed an IOP spike of greater than 
10 mmHg. In the POAG group, only 4 of 19 patients (21%) 
showed a postoperative IOP spike of greater than 5 mmHg, 
and none showed a postoperative IOP spike greater than 
10 mmHg. None of the patients received preoperative treat-
ment with antiglaucoma medications.
Discussion
This study was designed to determine the effects of SLT on 
IOP reduction in patients with PXFG glaucoma compared 
with POAG when used as initial or primary therapy. The 
results of this clinical trial demonstrate that SLT is a safe 
and effective method in lowering IOP, with mean IOP 
  reductions of 5.7 mmHg for the POAG group and 5.3 mmHg 
for the PXFG group over a follow-up period of 30 months.
The magnitude of the IOP reduction achieved in this study 
was similar to the IOP reductions we achieved in our initial 
multicenter pilot clinical study to investigate the IOP- 
lowering effects of SLT in patients on maximum medical 
therapy. In that study, the mean IOP reduction at 6 months 
was 5.8 mmHg in those patients who responded to SLT, with 
at least a 3 mmHg IOP reduction. In a longer-term random-
ized prospective clinical study comparing the IOP effects of 
SLT with ALT in patients with POAG on   medications, Damji 
et al9 found a mean IOP reduction of 6.5 mmHg at 12 months 
in those patients treated with SLT over 180 degrees. Eyes 
treated with ALT achieved an IOP reduction of 6.03 mmHg, 
which was not statistically different from the SLT-treated 
eyes.
In this study, the cumulative probability of success for 
patients with either POAG or PXFG to remain off medica-
tions for 2.5 years following SLT was approximately 75%. 
This result compares favorably with the GLT study, although 
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Figure 1 Mean iOP following SLT in patients with POAg and PXFg.
Abbreviations: iOP, intraocular pressure; POAg, primary open-angle glaucoma; PXFg, pseudoexfoliation glaucoma; SLT, selective laser trabeculoplasty.
Table 4 Kaplan-Meier life table analysis of time to failure after 
SLT POAg group without medications
Time after  
treatment  
(months)
Number  
of eyes
Number  
of failures
Number  
of eyes  
withdrawn
Cumulative   
probability  
of success
0–3 19 0 0 1
3–6 19 0 0 1
9–15 19 1 0 0.94
21–27 14 0 4 0.94
30–42 11 2 1 0.77
Abbreviations:  POAg,  primary  open  angle  glaucoma;  SLT,  selective  laser 
trabeculoplasty.
Table 5 Kaplan-Meier life table analysis of time to failure after 
SLT PXFg group without medications
Time after  
treatment  
(months)
Number  
of eyes
Number  
of failures
Number  
of eyes  
withdrawn
Cumulative   
probability  
of success
0–3 18 0 0 1
3–6 17 1 1 0.94
9–15 16 2 0 0.83
21–27 10 1 3 0.74
30–32 8 0 2 0.74
Abbreviations:  PXFg,  pseudoexfoliation  glaucoma;  SLT,  selective  laser 
trabeculoplasty.Clinical Ophthalmology
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the sample size in this study is relatively small and study 
conditions were not as rigid as the GLT study.5,6 Furthermore, 
patients received ALT over 360 degrees in the GLT study, 
whereas in this study the cumulative probability of success 
was reported only for SLT performed over 180 degrees.
The mean IOPs obtained in this study using SLT as initial 
therapy and probability of success also compared favorably 
with a 10-year follow-up study of the long-term efficacy of 
ALT by Shingelton et al.10 They reported a mean IOP at 
30 months of 18.1 ± 3.8 mmHg and demonstrated a cumula-
tive probability of success of 65% at 2.5 years following ALT 
treatment, where success was deemed as at least a 3 mmHg 
reduction of IOP from baseline, with stable visual field and 
nerve and no further laser or surgical intervention.
Comparing the rate of failure in the PXFG and POAG 
groups, this study suggests that eyes with PXFG fail sooner 
than eyes with POAG, which is similar to what is seen with 
ALT. Furthermore, a second SLT treatment was performed 
in four of the PXFG eyes. Although follow-up for these eyes 
was limited, all eyes responded with at least a 3 mmHg 
reduction of IOP and were maintained off medications for 
an additional 3–17 months.
In summary, the results of this study indicate that SLT is 
a safe and effective modality to treat eyes with both PXFG 
and POAG as initial therapy, with a 30-month cumulative 
probability of successfully remaining off medications of 
70% without significant adverse effects. Although only a small 
number of patients underwent a second SLT in this study, 
those eyes were able to extend the duration off medications.
Further large-scale randomized clinical trials are indi-
cated to demonstrate the repeatability of SLT and its long-
term effectiveness in patients with POAG and PXFG.
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Abbreviations: iOP, intraocular pressure; POAg, primary open-angle glaucoma; 
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